In response to the FDA approval of bevacizumab-bvzr for the treatment of metastatic carcinoma of the colon or rectum, the panel voted on the addition of bevacizumab-bvzr for this indication.

Based on a review of data and discussion, the panel consensus supported the inclusion of a footnote at each mention of bevacizumab that says, "An FDA-approved biosimilar is an appropriate substitute for bevacizumab". This is a category 2A recommendation.

In response to the FDA approvals of trastuzumab biosimilars for the treatment of HER2-positive metastatic colorectal cancer, the panel voted on the addition of trastuzumab biosimilars for this indication.

Based on panel discussion, the panel consensus supported the inclusion of a footnote at each mention of trastuzumab that says, "An FDA-approved biosimilar is an appropriate substitute for trastuzumab". This is a category 2A recommendation.

Panel discussion to reassess the inclusion of trastuzumab + (pertuzumab or lapatinib) for HER2-

Based on the discussion, the panel consensus supported the continued listing of trastuzumab + (pertuzumab or lapatinib) for HER2-amplified and RAS wild-type for second-line therapy and beyond for metastatic colon cancer. This recommendation changed from a category 2B to a category 2A.
amplified and RAS wild-type for second-line therapy and beyond for metastatic colon cancer as a category 2A recommendation.